Payment overview · 2025
General Payments
$221.56
11 reported records · 6 companies
Healthcare provider profile · identity verified
Sandra L Spedale, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MARRERO, LA · NPI 1104812544
Verified facts
What the public records show
CMS Open Payments records show Sandra L Spedale, MD received $221.56 in general payments during 2025 across 11 reported records.
GlaxoSmithKline, LLC. accounted for 32.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $72.83 | 32.9% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.05 | 27.6% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.99 | 10.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.44 | 10.6% | 1 | 2025 |
| Cipher Pharmaceuticals US LLC | Unresolved — no canonical attribution shown | $21.05 | 9.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.20 | 8.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $221.56 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $39.68 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.68 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.65 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $36.18 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $36.18 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.99 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $23.44 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $21.37 | 1 | 2025 |
Source payment records
|
|||||
| Natroba Normalized: natroba |
Drug | Cipher Pharmaceuticals US LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| Spinosad Normalized: spinosad |
Drug | Cipher Pharmaceuticals US LLC | $21.05 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $19.20 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 155 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 38 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 51 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
55 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
155 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
155 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 807 | 241 |
| Atorvastatin Calcium | Atorvastatin Calcium | 634 | 202 |
| Levothyroxine Sodium | Levothyroxine Sodium | 617 | 164 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 524 | 160 |
| Losartan Potassium | Losartan Potassium | 490 | 141 |
| Gabapentin | Gabapentin | 479 | 152 |
| Pantoprazole Sodium | Pantoprazole Sodium | 448 | 160 |
| Metoprolol Succinate | Metoprolol Succinate | 427 | 128 |
| Pravastatin Sodium | Pravastatin Sodium | 397 | 119 |
| Lisinopril | Lisinopril | 370 | 98 |
| Hydrochlorothiazide | Hydrochlorothiazide | 353 | 109 |
| Tramadol Hcl | Tramadol Hcl | 344 | 90 |
| Ozempic | Semaglutide | 316 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 248 | 92 |
| Metformin Hcl Er | Metformin Hcl | 247 | 81 |
| Trazodone Hcl | Trazodone Hcl | 226 | 83 |
| Metformin Hcl | Metformin Hcl | 224 | 66 |
| Furosemide | Furosemide | 222 | 81 |
| Potassium Chloride | Potassium Chloride | 215 | 83 |
| Sertraline Hcl | Sertraline Hcl | 212 | 69 |
| Januvia | Sitagliptin Phosphate | 204 | 52 |
| Alprazolam | Alprazolam | 194 | 46 |
| Meloxicam | Meloxicam | 193 | 74 |
| Lorazepam | Lorazepam | 183 | 69 |
| Jardiance | Empagliflozin | 181 | 42 |
| Fluticasone Propionate | Fluticasone Propionate | 172 | 87 |
| Omeprazole | Omeprazole | 159 | 50 |
| Eliquis | Apixaban | 155 | 36 |
| Montelukast Sodium | Montelukast Sodium | 153 | 50 |
| Nateglinide | Nateglinide | 147 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 146 | 42 |
| Allopurinol | Allopurinol | 139 | 37 |
| Carvedilol | Carvedilol | 137 | 45 |
| Ezetimibe | Ezetimibe | 136 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 129 | 35 |
| Hydralazine Hcl | Hydralazine Hcl | 121 | 31 |
| Tizanidine Hcl | Tizanidine Hcl | 119 | 36 |
| Alendronate Sodium | Alendronate Sodium | 115 | 38 |
| Pregabalin | Pregabalin | 110 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 103 | 25 |
| Clonazepam | Clonazepam | 92 | 24 |
| Valsartan | Valsartan | 91 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 89 | 25 |
| Mounjaro | Tirzepatide | 87 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 86 | 25 |
| Doxycycline Hyclate | Doxycycline Hyclate | 85 | 74 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 83 | 19 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 24 |
| Azithromycin | Azithromycin | 78 | 69 |
| Prednisone | Prednisone | 78 | 69 |
| Ropinirole Hcl | Ropinirole Hcl | 76 | 29 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 72 | 25 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 71 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 65 | 55 |
| Trulicity | Dulaglutide | 63 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 29 |
| Simvastatin | Simvastatin | 60 | 17 |
| Spironolactone | Spironolactone | 58 | 13 |
| Farxiga | Dapagliflozin Propanediol | 56 | 13 |
| Xarelto | Rivaroxaban | 56 | suppressed |
| Synthroid | Levothyroxine Sodium | 55 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 53 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 52 | 19 |
| Diclofenac Sodium | Diclofenac Sodium | 52 | 28 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 52 | 20 |
| Methylprednisolone | Methylprednisolone | 52 | 49 |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 51 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 51 | suppressed |
| Memantine Hcl | Memantine Hcl | 48 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 20 |
| Benazepril Hcl | Benazepril Hcl | 45 | 14 |
| Buspirone Hcl | Buspirone Hcl | 45 | 13 |
| Mirtazapine | Mirtazapine | 44 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 44 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 12 |
| Atenolol | Atenolol | 42 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 42 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 41 | 15 |
| Methocarbamol | Methocarbamol | 39 | 29 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 25 |
| Linzess | Linaclotide | 38 | 15 |
| Tresiba Flextouch U-100 | Insulin Degludec | 38 | 13 |
| Doxazosin Mesylate | Doxazosin Mesylate | 37 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 13 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 37 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 37 | 12 |
| Nystatin | Nystatin | 36 | 22 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 35 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 35 | suppressed |
| Nifedipine Er | Nifedipine | 34 | 13 |
| Bupropion Hcl Sr | Bupropion Hcl | 33 | 14 |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 33 | 11 |
| Glipizide Er | Glipizide | 33 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 33 | 13 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 33 | 27 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | suppressed |
| Celecoxib | Celecoxib | 31 | 15 |
| Terconazole | Terconazole | 31 | 12 |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 29 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 29 | suppressed |
| Belsomra | Suvorexant | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | 12 |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 23 |
| Dicyclomine Hcl | Dicyclomine Hcl | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 23 | 18 |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Amoxicillin | Amoxicillin | 20 | 19 |
| Baclofen | Baclofen | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 17 |
| Labetalol Hcl | Labetalol Hcl | 20 | suppressed |
| Mupirocin | Mupirocin | 20 | 15 |
| Nitroglycerin | Nitroglycerin | 20 | 11 |
| Tradjenta | Linagliptin | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 19 | 16 |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 18 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 16 | suppressed |
| Praluent Pen | Alirocumab | 16 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Verapamil Er | Verapamil Hcl | 12 | suppressed |
| Euthyrox | Levothyroxine Sodium | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $221.56 · 11 records | GlaxoSmithKline, LLC. | ABRYSVO, AREXVY, COMIRNATY, Dexcom G6 Transmitter, ELIQUIS, LINZESS, Natroba, PREVNAR 20, QULIPTA, SHINGRIX, Spinosad, TRELEGY ELLIPTA, UBRELVY | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error